Publicaciones (56) Publicaciones de AZAEL DAVID FREITES MARTINEZ

2023

  1. Alopecia en supervivientes de cáncer de mama en tratamiento con terapia hormonal

    Más dermatología, Núm. 42, pp. 11-12

  2. Clinical characterization and treatment outcomes of follicular cutaneous immune–related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study

    Journal of the American Academy of Dermatology, Vol. 88, Núm. 3, pp. 718-720

  3. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study

    Cancers, Vol. 15, Núm. 14

  4. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management

    International Journal of Dermatology, Vol. 62, Núm. 8, pp. 1020-1025

  5. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases

    Melanoma research, Vol. 33, Núm. 2, pp. 155-158

  6. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations

    The Lancet Oncology, Vol. 24, Núm. 4, pp. e172-e185

  7. Shared decision-making quality and decisional regret in patients with low-risk superficial basal cell carcinoma: A prospective, multicenter cohort study

    JAAD International, Vol. 13, pp. 159-163

  8. Supportive oncodermatology practices in Europe and the USA

    Journal of the European Academy of Dermatology and Venereology

2022

  1. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

    British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969

  2. Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

    JAMA Dermatology

  3. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Journal of the European Academy of Dermatology and Venereology, Vol. 36, Núm. 3, pp. 332-350

  4. Histopathology of Dermatologic Complications of Tattoos

    American Journal of Dermatopathology, Vol. 44, Núm. 9, pp. 632-649

  5. Sample CME manuscript submission: Response to the article by Pham et al entitled “Review BRAF inhibition and the spectrum of granulomatous reactions”

    Journal of the American Academy of Dermatology

  6. Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia

    Gynecologic Oncology Reports, Vol. 44

2021

  1. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 1, pp. 90-92

2020

  1. Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients with Cancer

    JAMA Dermatology, Vol. 156, Núm. 9, pp. 963-972

  2. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

    Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 6, pp. 1340-1347

  3. Smartphones in Medical Photography

    Photography in Clinical Medicine (Springer International Publishing), pp. 191-197

2019

  1. Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

    JAMA Dermatology, Vol. 155, Núm. 6, pp. 724-728

  2. Clinical Characterization of Immunotherapy-Related Pruritus among Patients Seen in 2 Oncodermatology Clinics

    JAMA Dermatology